Photo by nci from unsplash
TPS9117Background: Afatinib and pembrolizumab have demonstrated improvements in the outcomes of pts with SCC of the lung and are approved as monotherapy. Afatinib is a selective and irreversible Er... Click to show full abstract
TPS9117Background: Afatinib and pembrolizumab have demonstrated improvements in the outcomes of pts with SCC of the lung and are approved as monotherapy. Afatinib is a selective and irreversible Er...
Keywords:
combination pembrolizumab;
pembrolizumab patients;
patients pts;
afatinib combination;
scc lung;
lung
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!